Document is current

Article History

Accepted: 27 October 2022

First Online: 25 November 2022

Declarations

:

: No funding was received to write this letter.

: Dr Del Porto reports being an active speaker and board advisor at Daiichi Sankyo Brasil, Pfizer, Janssen Pharmaceutical, Cristalia Produtos Quimicos e Farmaceuticos, Libbs Farmaceutica, Wyeth, Ache Laboratorios Farmaceuticos, and Eurofarma outside the submitted work. Dr Lacerda has received consulting fees from Janssen Pharmaceutical, Daiichi Sankyo, Cristalia Produtos Químicos e Farmacêuticos, H. Lundbeck A/S, Pfizer, LivaNova, Raras CRO, Mantecorp Indústria Química e Farmacêutica, Libbs Farmacêutica, EMS, Pfizer, Apsen Farmacêutica and Sanofi-Aventis over the last 24 months and has received research fees from Boehringer-Ingelheim, Janssen Pharmaceutical, Eli Lilly, Genentech, Novo Nordisk, Biophytis, Celltrion, Novartis, EOM, Genova, Cellavita, Azidus, PPD, IQVIA, Parexel and FQM Farma outside the submitted work. The remaining authors declare no potential conflicts of interest.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors conceived and wrote the letter.